To date (May 3rd), the WHO has reported a total of 3,356,205 confirmed cases of COVID-19 and 238,730 confirmed deaths, with the number of infections still rising globally. Since its discovery in late December 2019 in Wuhan (China), SARS-CoV-2 has been detected all over the world, leading to the COVID-19 outbreak being declared a pandemic by the WHO on March 11th, 2020. SARS-CoV-2 is unique in terms of its high transmissibility, pathogenicity and mortality when compared to other coronaviruses.
Globally, pharmaceutical companies and research institutions are ramping up efforts to tackle SARS-CoV-2 and achieve a strong decrease in COVID-19 incidents. However, research on novel SARS-CoV-2 is still in the early stages of development. BioGenes is participating in the global fight against COVID-19 by providing its knowledge and established technology in highly sophisticated antibody development for diagnostic purposes and research.
With Excellence in Antibody and ELISA Development, we would appreciate supporting your COVID-19 research, and development of assays and diagnostic tests. BioGenes’ personnel continue working in our labs with the goal of generating customized monoclonal and polyclonal antibodies suitable for the detection of SARS-CoV-2 proteins of choice, with high sensitivity and specificity. The development of anti-idiotypic antibodies (anti-ID), e.g. for use as assay controls, can be particularly challenging. BioGenes’ thorough understanding of anti-ID development and our great antibody track record makes us an optimal partner for COVID-19 related antibody projects. BioGenes also offers services for ELISA set up and qualification, e.g. for protein quantification to enhance production cell line development, complementing our antibody manufacturing know-how.
With recommended safety measures in place to prevent the spread of COVID-19, BioGenes is operating at normal speed. We can assure you of the highest level of quality and service for your upcoming projects. We would be happy to arrange a phone call with our experts from Project Management and the lab to discuss any details.